| HOME >> BIOLOGY >> TECHNOLOGY |
PARSIPPANY, N.J., Jan. 28 /PRNewswire/ -- Ferring Pharmaceuticals Inc. has announced that its hyaluronic acid therapy, EUFLEXXA(TM) (1% sodium hyaluronate) will serve as the title sponsor of the EUFLEXXA National Senior Games Hockey Championships and the EUFLEXXA GeezerJock of the Year Award.
"This is such a tremendous opportunity for both our brand and for senior athletes," said Alex Drigan, Product Manager, EUFLEXXA(TM). "We support all that the National Senior Games Association (NSGA) and Masters Athlete magazine do to promote healthy, active aging and hope that these sponsorships will help more seniors realize their athletic dreams."
"We are thrilled that EUFLEXXA(TM) is helping us ensure that more senior athletes will be able to compete in the sports that they love on the national level," said Phil Godfrey, President and Chief Executive Officer of NSGA. "Ferring is a loyal supporter of the NSGA's efforts and we truly appreciate how much this sponsorship does for advancing these efforts."
The EUFLEXXA(TM) GeezerJock of the Year Award is the premier award program presented by Masters Athlete magazine. The program recognizes excellence in Masters athletics. In addition to a single overall winner, the program also recognizes male and female winners in five age categories and a GeezerJock Executive of the Year award, recognizing the association head who has done the most to advance Masters athletics.
"We are excited that EUFLEXXA(TM) is sponsoring the GeezerJock of the Year Award," said Brian Reilly, publisher of Masters Athlete magazine. "Together with their sponsorships of major senior sporting events, it's clear that EUFLEXXA(TM) is deeply committed to improving the quality of life for Masters athletes."
About EUFLEXXA(TM)
EUFLEXXA(TM) (1% sodium hyaluronate) is the first and only non-avian
derived hyaluronic acid approved in the U.S. for the treatment of pain
caused by knee osteoarthritis and is indicated for a th
'/>"/>
| SOURCE Ferring Pharmaceuticals Inc. Copyright©2008 PR Newswire. All rights reserved |